ArticleHeart and vessels2016
Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Comparative efficacy of different drugs in acute heart failure with renal dysfunction: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.The Journal of international medical research · 2019Pooled it
- Pooled it
- Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.Heart and vessels · 2017Trial
- Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Article
- Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation.Heart and vessels · 2022Article
- Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction.Heart and vessels · 2022Article
- Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation.Heart and vessels · 2022Article
- Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.ESC heart failure · 2021Article
- Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.Heart and vessels · 2021Observational
- Initiation and long-term use of tolvaptan for patients with worsening heart failure through hospital and clinic cooperation.Nagoya journal of medical science · 2021Article
- Long-Term Tolvaptan Treatment in Refractory Heart Failure.Circulation reports · 2019Article
- Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.Heart and vessels · 2019Article
- The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.Heart and vessels · 2018Article
- Good response to tolvaptan shortens hospitalization in patients with congestive heart failure.Heart and vessels · 2018Observational
- The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.Heart and vessels · 2018Observational
- Article
- Nutritional screening based on the controlling nutritional status (CONUT) score at the time of admission is useful for long-term prognostic prediction in patients with heart failure requiring hospitalization.Heart and vessels · 2017Article
- Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.Clinical and experimental nephrology · 2017Observational
- Impact of decreased serum albumin levels on acute kidney injury in patients with acute decompensated heart failure: a potential association of atrial natriuretic peptide.Heart and vessels · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tolvaptan, a vasopressin type 2 receptor antagonist, has an aquaretic effect without affecting renal function. The effects of long-term tolvaptan administration in heart failure patients with renal dysfunction have not been clarified. Here, we assessed the clinical benefit of tolvaptan during a 6-month follow-up in acute decompensated heart failure (ADHF) patients with severe chronic kidney disease (CKD; estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m(2)). We compared 33 patients with ADHF and severe CKD who were administered tolvaptan in addition to loop diuretics (TLV group), with 36 patients with ADHF and severe CKD who were administered high-dose loop diuretics (≥40 mg) alone (LD group). Alterations in serum creatinine and eGFR levels from the time of hospital discharge to 6-month follow-up were significantly different between the groups, with those in the TLV group being more favorable. Furthermore, Kaplan-Meier analysis revealed that rehospitalization for heart failure (HF) was significantly lower in the TLV group compared with the LD group. In ADHF patients with severe CKD, tolvaptan use for 6 months reduced worsening of renal function and rehospitalization rates for HF when compared with conventional diuretic therapy. In conclusion, tolvaptan could be a safe and effective agent for long-term management of HF and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.